FOSTER CITY, Calif.--(BUSINESS WIRE)--Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease, today announced that the Company’s management team will present at two upcoming investor conferences.
Piper Sandler EASL Takeaway Series Featuring Experts & Drug Developers
- Date: Wednesday, September 2nd
- Time: 11:30 a.m. ET
- Speakers: Senthil Sundaram, CEO and Erin Quirk, M.D., President and CMO
Citi’s 15th Annual BioPharma Virtual Conference
- Date: Tuesday, September 8th
- Time: 3:30 p.m. ET
- Speaker: Senthil Sundaram, CEO
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease including a pipeline of orally administered drug candidates for the treatment of non-alcoholic steatohepatitis (NASH). The company’s liver-selective FXR-agonist, TERN-101, is currently enrolling a multi-center, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate efficacy, safety, and pharmacokinetics in 96 presumed NASH patients who receive placebo or TERN-101 at various dose levels for 12 weeks. Terns announced in July 2020 positive Phase 1 clinical data for its highly-selective SSAO inhibitor, TERN-201, demonstrating potent and sustained target engagement. In addition, the company is actively planning to initiate clinical studies for its thyroid hormone receptor-β agonist TERN-501 as monotherapy and in combination with its other pipeline assets for NASH, as well as advancing its small molecule GLP-1R agonist program. Terns’ investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.
For more information, visit www.ternspharma.com